Gavan Technologies

**Product and the concrete problem it solves.** Gavan Technologies addresses a stubborn formulation problem in the food industry: butter, milk fat, palm oil, and coconut oil provide texture, lubrication, melt behavior, flavor delivery, and processing stability that conventional plant oils often cannot match. Removing those fats can improve nutrition or sustainability but frequently creates dry, brittle, watery, or otherwise disappointing products, while many substitute formulations depend on long ingredient lists, hydrogenation, or emulsifiers that work against clean-label positioning. Gavan's commercial answer is Fatrix, a plant-protein-based fat system designed as a functional ingredient rather than a consumer-facing packaged-food brand. The company describes it as a one-to-one butter replacement in a broad range of bakery products and as a way to reduce total and saturated fat in dairy alternatives, hybrid meat, and savory foods. The practical promise is not simply that Fatrix contains less saturated fat; it is that food manufacturers can reformulate existing products while preserving the sensory and manufacturing behavior consumers expect. Public material describes Fatrix as a smooth, stable, flavorless gel made from protein isolate, vegetable oil, and water, with no trans fats because it is not hydrogenated. Gavan says the ingredient can carry flavors, vitamins, and omega-3, and can be adjusted for different fat-to-water ratios and textures. Those claims position the company at the intersection of healthier formulation, alternative proteins, and industrial ingredient substitution.

**Core technology and how it actually works.** Gavan's technical foundation is a proprietary, patented protein-extraction and modification platform. According to the company's technology page, the process extracts high-purity proteins from a plant source while preserving their natural physical structure and functionality, then continues through multiple extraction stages until the source is fully consumed. The stated zero-waste architecture matters because many ingredient processes capture only one desired fraction and leave lower-value biomass behind; Gavan's model is to produce multiple useful outputs from the same source. The extracted proteins are then modified to control stability, odor, taste, and color for a specific application. For Fatrix, the functional protein acts as a binder that holds vegetable oil and water together in a high-performance gel or emulsion. This is the key mechanism behind the product's claimed heat stability and fat- and water-holding capacity: instead of asking liquid plant oil to behave like solid or semi-solid animal fat on its own, the protein structure creates a controllable matrix around the oil and aqueous phase. Independent public sources do not disclose the exact plant feedstocks, extraction conditions, protein composition, particle-size distribution, shear history, or full patent claims, so the record should not treat the platform as technically reproduced outside the company. Even so, the mechanism is more specific than generic plant-based-food language. The important diligence question is whether preserving protein structure during extraction produces a repeatable, food-grade ingredient at industrial cost, and whether the modification platform can tune performance without adding processing complexity that cancels the claimed economic and sustainability benefits.

**Market, customers, and go-to-market.** Gavan sells into the business-to-business food-ingredient chain, where adoption depends on formulation performance, regulatory status, supply reliability, and the economics of changing a recipe. The company is initially focused on bakery and dairy applications because butter and milk fat are highly visible performance bottlenecks in croissants, brioche, laminated dough, cream cheese, spreads, sauces, yogurt, ice cream, and puddings. Its applications page also lists alternative meat and savory products, expanding the opportunity into burgers and sausages where melt point, juiciness, and fat retention matter. The commercial motion is consultative: Gavan says it works with customers from ideation and sample testing through technical workshops, co-development, scale-up, regulatory support, and launch readiness. That workflow is appropriate for an ingredient platform because a manufacturer rarely adopts a substitute from a specification sheet alone; it must run the material through its own mixers, ovens, fillers, shear conditions, and shelf-life protocols. The December 2024 funding announcement said Gavan planned a pilot production facility in Europe, with a targeted April 2025 start and 200 metric tons of annual capacity, to support European bakery and dairy commercialization. FoodNavigator reported that CEO Itai Cohen expected future facilities to be located near strategic customers in Europe and the United States. The public record does not name paying customers, signed supply agreements, revenue, repeat-order rates, or the current operating status of the European plant, so the go-to-market case is credible but still requires customer and production verification.

**Traction, funding, and third-party validation.** Gavan has a stronger financing and ecosystem record than a purely conceptual food-tech project. The company says it was founded in 2018 and previously raised $2.5 million in seed funding before announcing an $8 million Series A in December 2024. MoreVC led the Series A, with participation from Lever VC, EIT Food, and DarkBoot Group. The stated use of proceeds was concrete: establish European pilot production and expand commercial activity in bakery and dairy. FoodNavigator independently reported the round, the intended 200-ton production capacity, and the company's plan to engage customers through product testing. A 2023 Food Ingredients Global article described the protein-preserving extraction process, Fatrix's ability to reduce saturated fat by up to 80 percent in finished products, and early work with potential customers. The Good Food Institute Israel's alternative-protein ecosystem report lists Gavan's 2018 founding, Itai Cohen as CEO, and Allen Hazan and Uri Jeremias as founders, while an Israel Innovation Authority program listing identifies Gavan as an Israeli food-tech company and reports 105 employees in its program data. The employee figure should be treated as dated program evidence rather than a current headcount disclosure. Gavan also says Fatrix is already approved for market and does not require novel-food approval because it uses familiar food ingredients, but that regulatory statement is company-supplied and should be checked jurisdiction by jurisdiction. Overall, third-party validation supports a real Israeli company with a funded commercialization plan and an unusually concrete technology claim; it does not yet establish scaled manufacturing, durable customer demand, or independent nutritional and life-cycle performance.

**Founders and team background.** The public founder record is compact but relevant to the operating problem. Itai Cohen is identified as co-founder and CEO in the company's funding announcement and in industry coverage. The Good Food Institute Israel lists Allen Hazan and Israeli chef Uri Jeremias alongside Cohen as founders. Jeremias brings food-product and culinary perspective that is useful for a company whose differentiation is ultimately judged by mouthfeel, aroma, texture, and cooking performance rather than by a laboratory metric alone. Gavan's public material also identifies Irit Ventura as Vice President of R&D in a Technion Canada feature, and describes a team working across protein extraction, formulation, and food applications. This combination suggests a product-development organization capable of translating materials science into manufacturer-ready recipes, although public sources do not provide complete biographies, academic credentials, headcount by function, or the full technical leadership roster. The team question is therefore not whether the founders understand food at all, but whether the company has enough process engineering, quality assurance, regulatory, manufacturing, and commercial-ingredient experience to move from a promising formulation to consistent lots delivered on schedule. Deep-tech food companies often fail at that interface: a formula can work in a pilot kitchen yet become expensive or unstable when exposed to industrial shear, long transport, seasonal feedstock variation, and customer-specific equipment. Gavan's co-development model and reported R&D leadership are positive indicators, but the database should not infer patent ownership, manufacturing expertise, or customer access beyond what the sources establish.

**Competitive dynamics.** Gavan competes against several distinct approaches rather than one direct rival. Traditional dairy fats and commodity butter remain the reference product because they are familiar, functional, and deeply embedded in industrial recipes. Plant-oil and oleogel specialists, including companies working on structured oils and emulsions, compete on the same promise of lower saturated fat and improved sustainability. Alternative-protein ingredient companies such as Ingredion, Roquette, BENEO, and ADM can bundle protein isolates, emulsifiers, starches, and formulation support into relationships with large food manufacturers. Newer food-tech companies such as Enough, MycoTechnology, and other fermentation or biomass platforms may compete indirectly by supplying ingredients that improve the nutritional and sensory profile of finished foods. Gavan's claimed edge is the combination of a protein-preserving extraction process, a zero-waste source-utilization model, and a tunable fat matrix that can be adapted across categories. Its sales approach also creates a potential workflow advantage: by joining the customer's formulation process early, Gavan can accumulate application know-how and reduce the risk that a technically good ingredient is rejected for failing a production constraint. These advantages are not yet a proven moat. Large ingredient incumbents have stronger manufacturing networks, purchasing leverage, quality systems, and regulatory teams, while specialist competitors may have more advanced scale-up data or narrower focus. The decisive comparison will be total cost in the customer's recipe, performance across processing and shelf life, supply consistency, sensory test results, and whether the zero-waste extraction claim survives full mass-balance and life-cycle analysis.

**Defense, security, and resilience dual-use relevance.** Gavan's strategic relevance is primarily food-system resilience rather than a direct defense product. Israel and allied countries are exposed to disruption in agricultural inputs, shipping lanes, animal-disease outbreaks, energy and water constraints, and volatile commodity prices. A stable, scalable ingredient platform that reduces dependence on animal fats and can produce several functional ingredients from a single plant source could support more flexible food manufacturing during ordinary supply-chain stress or emergency conditions. The resilience case is strongest if Gavan can localize production near customers, use regionally available feedstocks, and maintain quality when imported fats or specialty emulsifiers are scarce. Fatrix could also help institutional and military food suppliers formulate shelf-stable, lower-saturated-fat products, but no defense customer, military ration program, government contract, or fielded security use is publicly disclosed. The core technology is plausibly dual-use in the broad civil-resilience sense: its extraction and formulation capabilities can strengthen food availability and substitution capacity, while the same manufacturing and formulation knowledge has commercial applications in bakery, dairy alternatives, meat alternatives, and nutrition. That is a weaker dual-use profile than a company building sensors, cyber controls, or autonomous systems, so the dual-use score should remain moderate. Strategic diligence should focus on whether the process can operate with local crops, whether products remain safe and nutritious under constrained cold-chain conditions, and whether production can be distributed enough to matter during a real disruption. Without those data, Gavan is a food-security and industrial-biotechnology watch item, not a defense supplier.

**Growth stage, trajectory, and key diligence risks.** Gavan is best classified as early-to-mid commercialization: it has operated since 2018, raised a meaningful Series A, has a defined flagship product, and describes customer co-development and planned European production, but public evidence does not establish recurring revenue, scaled sales, or a completed industrial rollout. The trajectory depends on turning technical versatility into a small number of repeatable beachhead formulations, proving that Fatrix can be manufactured at competitive cost, and converting pilot customers into long-term ingredient supply contracts. The most important diligence risks are: (1) **scale-up risk**, because protein extraction, emulsion formation, and aseptic or food-grade handling can behave differently at industrial throughput; (2) **feedstock and yield risk**, because a zero-waste process must prove mass balance, seasonal robustness, and attractive economics across sources; (3) **sensory and process risk**, because a product that works in brioche may not work equally well in cream cheese, ice cream, or hybrid meat; (4) **customer adoption risk**, since large manufacturers are conservative and may require long qualification cycles even when a substitute performs well; (5) **incumbent response**, as major ingredient suppliers can copy functionality, bundle alternatives, or use existing distribution to compress pricing; (6) **regulatory and claims risk**, including verification of novel-food status, nutrition claims, allergen controls, and country-specific labeling; and (7) **disclosure risk**, because current plant sources, patent scope, production status, customer names, revenue, gross margins, and headcount are not fully public. The next milestones that would materially improve the thesis are independently measured product performance, a verified operating production line, named commercial launches, repeat purchase data, transparent environmental mass balance, and evidence that Fatrix's economics remain attractive after logistics and quality-control costs.